arGEN-X SE ADR (ARGX): Price and Financial Metrics


arGEN-X SE ADR (ARGX): $380.90

-1.20 (-0.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARGX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ARGX POWR Grades

  • Growth is the dimension where ARGX ranks best; there it ranks ahead of 65.91% of US stocks.
  • ARGX's strongest trending metric is Sentiment; it's been moving down over the last 177 days.
  • ARGX ranks lowest in Quality; there it ranks in the 0th percentile.

ARGX Stock Summary

  • For ARGX, its debt to operating expenses ratio is greater than that reported by only 5.41% of US equities we're observing.
  • With a price/sales ratio of 706.32, ARGENX SE has a higher such ratio than 99.29% of stocks in our set.
  • Revenue growth over the past 12 months for ARGENX SE comes in at -47.95%, a number that bests just 3.98% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ARGENX SE are SWKS, YMAB, API, APLS, and GWH.
  • Visit ARGX's SEC page to see the company's official filings. To visit the company's web site, go to www.argenx.com.

ARGX Stock Price Chart Interactive Chart >

Price chart for ARGX

ARGX Price/Volume Stats

Current price $380.90 52-week high $407.93
Prev. close $382.10 52-week low $249.50
Day low $371.85 Volume 297,200
Day high $385.27 Avg. volume 234,978
50-day MA $382.63 Dividend yield N/A
200-day MA $359.52 Market Cap 21.07B

arGEN-X SE ADR (ARGX) Company Bio


argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted recent achievements from its late-stage immunology pipeline driven by its FcRn antagonist, efgartigimod. Additionally, the Company announced interim data from the Phase 2 CULMINATE trial of cusatuzumab in development with Cilag GmbH International, an affiliate of Janssen, and provided financial guidance for 2021. (Source:Wiki)


ARGX Latest News Stream


Event/Time News Detail
Loading, please wait...

ARGX Latest Social Stream


Loading social stream, please wait...

View Full ARGX Social Stream

Latest ARGX News From Around the Web

Below are the latest news stories about ARGENX SE that investors may wish to consider to help them evaluate ARGX as an investment opportunity.

argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

January 16, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the e

Yahoo | January 16, 2023

argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline

Reported $402 million in preliminary* full-year 2022 global net VYVGART sales ADHERE topline results now expected in second quarter of 2023; Stage B enrollment has surpassed projected target of 130 patients Registrational trial of efgartigimod in thyroid eye disease (TED) to start in 2023; additional proof-of-concept trials to start in ANCA-associated vasculitis and antibody mediated rejection (AMR) Submission for marketing approval in Japan of VYVGART for immune thrombocytopenia (ITP) expected

Yahoo | January 9, 2023

argenx to Present at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repla

Yahoo | January 3, 2023

argenx Appoints Ana Cespedes to Board of Directors

December 12, 2022 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as f

Yahoo | December 12, 2022

argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia

First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease VYVGART showed rapid, clinically and statistically significant improvements in platelet counts compared with placebo; safety profile consistent with previous trials Topline data from ADVANCE-SC trial of subcutaneously (SC) administered VYVGART for ITP expected in second half of 2023 Amsterdam, the Netherlands – December 10, 2022 – argenx SE (Euron

Yahoo | December 10, 2022

Read More 'ARGX' Stories Here

ARGX Price Returns

1-mo 1.36%
3-mo -2.08%
6-mo 7.30%
1-year 47.21%
3-year 157.03%
5-year 359.86%
YTD 0.55%
2022 8.18%
2021 19.08%
2020 83.21%
2019 67.09%
2018 52.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7433 seconds.